GC Wealth Management RIA LLC Has $213,000 Position in DexCom, Inc. (NASDAQ:DXCM)

GC Wealth Management RIA LLC reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 8.1% in the 4th quarter, HoldingsChannel.com reports. The firm owned 2,742 shares of the medical device company’s stock after selling 242 shares during the quarter. GC Wealth Management RIA LLC’s holdings in DexCom were worth $213,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. King Luther Capital Management Corp raised its position in DexCom by 4.2% during the fourth quarter. King Luther Capital Management Corp now owns 222,132 shares of the medical device company’s stock valued at $17,275,000 after acquiring an additional 8,887 shares in the last quarter. Marathon Trading Investment Management LLC bought a new position in shares of DexCom in the fourth quarter valued at approximately $1,217,000. Independent Advisor Alliance bought a new position in shares of DexCom in the fourth quarter valued at approximately $244,000. Daiwa Securities Group Inc. raised its position in shares of DexCom by 5.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 80,979 shares of the medical device company’s stock valued at $6,298,000 after purchasing an additional 3,880 shares during the period. Finally, AlphaQuest LLC raised its position in shares of DexCom by 428.8% in the fourth quarter. AlphaQuest LLC now owns 8,165 shares of the medical device company’s stock valued at $635,000 after purchasing an additional 6,621 shares during the period. Institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. This represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 45,083 shares of company stock worth $3,826,604 over the last 90 days. Corporate insiders own 0.30% of the company’s stock.

DexCom Stock Down 0.7 %

DXCM opened at $70.26 on Wednesday. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The firm’s fifty day moving average price is $84.53 and its two-hundred day moving average price is $76.98. The company has a market capitalization of $27.46 billion, a P/E ratio of 49.13, a P/E/G ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on DXCM. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Citigroup lifted their price target on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Tuesday, March 4th. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Canaccord Genuity Group lifted their price target on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Finally, Morgan Stanley raised their price objective on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.82.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.